[Clinical study on regulatory effect of liandai Capsule on p21ras and mutant p53 protein expression in gastrointestinal neoplasm]

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2001 Oct;21(10):736-8.
[Article in Chinese]

Abstract

Objective: To study the regulatory effect of Liandai Capsule on p21ras and mutant p53 protein expression in gastrointestinal (GI) neoplasm.

Methods: Forty-five patients of GI neoplasm in middle or advanced stage were enrolled and divided randomly into the treated group and the control group to observe the changes of their serum p21ras and mutant p53 protein expression as well as their quality of life (QOL) before and after treatment.

Results: The content of p21ras and mutant p53 protein expression in the treated group decreased significantly and QOL improved after treatment, P < 0.05 or P < 0.01, while these changes in the control group were not shown.

Conclusion: Liandai Capsule has regulatory effect on p21ras and mutant p53 protein expression in GI neoplasm.

Publication types

  • Clinical Trial
  • English Abstract
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / metabolism
  • Adult
  • Aged
  • Capsules
  • Colonic Neoplasms / genetics
  • Colonic Neoplasms / metabolism
  • Drugs, Chinese Herbal / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Phytotherapy*
  • Proto-Oncogene Proteins p21(ras) / biosynthesis*
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Quality of Life
  • Stomach Neoplasms / genetics
  • Stomach Neoplasms / metabolism*
  • Tumor Suppressor Protein p53 / biosynthesis*
  • Tumor Suppressor Protein p53 / genetics

Substances

  • Capsules
  • Drugs, Chinese Herbal
  • Tumor Suppressor Protein p53
  • HRAS protein, human
  • Proto-Oncogene Proteins p21(ras)